Aquestive Therapeutics, Inc. (AQST)
USD 3.0
(0.0%)
USD 3.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.18 Million USD | 67.73% |
| 2022 | -39.58 Million USD | -22.51% |
| 2021 | -45.11 Million USD | 19.89% |
| 2020 | -39.15 Million USD | 17.82% |
| 2019 | -53.87 Million USD | -7.53% |
| 2018 | -50.32 Million USD | -1412.01% |
| 2017 | 2.56 Million USD | 25.23% |
| 2016 | 2.94 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 260 Thousand USD | 103.09% |
| 2024 Q1 | -8.75 Million USD | -95.47% |
| 2024 Q3 | -8.29 Million USD | -2850.77% |
| 2023 Q2 | -3.79 Million USD | -138.26% |
| 2023 Q1 | 9.9 Million USD | 193.05% |
| 2023 FY | - USD | 67.73% |
| 2023 Q4 | -3.44 Million USD | -44.89% |
| 2023 Q3 | -2.37 Million USD | 37.3% |
| 2022 FY | - USD | -22.51% |
| 2022 Q1 | -9.01 Million USD | 21.87% |
| 2022 Q4 | -10.64 Million USD | -29.04% |
| 2022 Q3 | -8.25 Million USD | 31.59% |
| 2022 Q2 | -12.06 Million USD | -33.87% |
| 2021 FY | - USD | 19.89% |
| 2021 Q1 | -7.77 Million USD | 50.33% |
| 2021 Q2 | -5.4 Million USD | 30.48% |
| 2021 Q3 | -7.23 Million USD | -33.88% |
| 2021 Q4 | -11.53 Million USD | -59.49% |
| 2020 Q4 | -15.64 Million USD | -19.22% |
| 2020 Q2 | 1.21 Million USD | 109.4% |
| 2020 FY | - USD | 17.82% |
| 2020 Q1 | -12.87 Million USD | -30.91% |
| 2020 Q3 | -13.12 Million USD | -1184.3% |
| 2019 Q2 | -17.81 Million USD | -39.15% |
| 2019 FY | - USD | -7.53% |
| 2019 Q4 | -9.83 Million USD | 3.17% |
| 2019 Q3 | -10.15 Million USD | 42.98% |
| 2019 Q1 | -12.8 Million USD | -6.29% |
| 2018 Q2 | -32.7 Million USD | -620.65% |
| 2018 FY | - USD | -1412.01% |
| 2018 Q4 | -12.04 Million USD | -46.09% |
| 2018 Q3 | -8.24 Million USD | 74.8% |
| 2018 Q1 | 6.28 Million USD | 199.89% |
| 2017 Q2 | -3.11 Million USD | -281.98% |
| 2017 Q3 | 11.37 Million USD | 465.85% |
| 2017 Q1 | 1.7 Million USD | 0.0% |
| 2017 Q4 | -6.28 Million USD | -155.27% |
| 2017 FY | - USD | 25.23% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 100.787% |
| Theratechnologies Inc. | -10.31 Million USD | 111.461% |
| Safety Shot Inc | -12.18 Million USD | 109.7% |
| Cosmos Health Inc. | -17.06 Million USD | 106.928% |
| Cronos Group Inc. | -72.14 Million USD | 101.638% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 100.128% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 103.276% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 96.719% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 136.764% |
| ProPhase Labs, Inc. | -14.82 Million USD | 107.972% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 126.122% |
| Dynavax Technologies Corporation | 9.66 Million USD | 87.772% |
| Radius Health, Inc. | 38.31 Million USD | 96.915% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 150.276% |
| Alvotech | -484.86 Million USD | 100.244% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 130.907% |
| Alpha Teknova, Inc. | -25.53 Million USD | 104.628% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 100.744% |
| SCYNEXIS, Inc. | 73.47 Million USD | 98.391% |
| Harrow Health, Inc. | 9.72 Million USD | 87.843% |
| Biofrontera Inc. | -18.45 Million USD | 106.405% |
| DURECT Corporation | -24.68 Million USD | 104.789% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 98.797% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 98.919% |
| OptiNose, Inc. | -15.55 Million USD | 107.6% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 95.5% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 266.28% |
| SIGA Technologies, Inc. | 84.15 Million USD | 98.596% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -45.567% |
| Shineco, Inc. | -26.55 Million USD | 104.451% |
| Phibro Animal Health Corporation | 84.6 Million USD | 98.603% |
| Procaps Group S.A. | 104.02 Million USD | 98.864% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 114.07% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 132.673% |
| Viatris Inc. | 3.51 Billion USD | 99.966% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 130.907% |
| Rockwell Medical, Inc. | -4.69 Million USD | 125.181% |
| Incannex Healthcare Limited | -18.5 Million USD | 106.388% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 216.798% |
| Tilray Brands, Inc. | -72.84 Million USD | 101.623% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 99.617% |
| PetIQ, Inc. | 81.48 Million USD | 98.549% |
| Silver Spike Investment Corp. | 7.34 Million USD | 83.897% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 99.716% |
| Journey Medical Corporation | 1.92 Million USD | 38.47% |
| Alimera Sciences, Inc. | 7.27 Million USD | 83.755% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 128.064% |
| Assertio Holdings, Inc. | -222.44 Million USD | 100.531% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 129.619% |
| Embecta Corp. | 245.4 Million USD | 99.518% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 105.901% |
| Procaps Group, S.A. | 104.02 Million USD | 98.864% |
| PainReform Ltd. | -9.56 Million USD | 112.352% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 100.793% |
| Hempacco Co., Inc. | -12.77 Million USD | 109.254% |
| Talphera, Inc. | -9.84 Million USD | 112.01% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 99.274% |
| Alvotech | -484.86 Million USD | 100.244% |
| Lantheus Holdings, Inc. | 491 Million USD | 99.759% |
| Kamada Ltd. | 21.53 Million USD | 94.511% |
| Indivior PLC | 66 Million USD | 98.209% |
| Currenc Group, Inc. | -1.9 Million USD | 162.192% |
| Evoke Pharma, Inc. | -7.29 Million USD | 116.209% |
| Flora Growth Corp. | -45.87 Million USD | 102.577% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 105.901% |
| Evolus, Inc. | -41.81 Million USD | 102.827% |
| HUTCHMED (China) Limited | 25.52 Million USD | 95.37% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 99.51% |
| Akanda Corp. | -27.73 Million USD | 104.262% |